Ralf Liebhold / Shutterstock.com
Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s (GSK) Coreg heart drug (Carvedilol).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva Pharmaceuticals, Coreg, GlaxoSmithKline, Coreg, Federal Circuit, Carve-out, Skinny Label